Ohtuvayre denied as non-formulary by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ohtuvayre as Non-Formulary

Ohtuvayre (ensifentrine) is a newer class of inhaled COPD maintenance therapy — a dual PDE3/PDE4 inhibitor — that many commercial formularies have not yet placed on a preferred tier. A non-formulary denial from Aetna means the drug is either absent from your specific plan's drug list or placed at a tier that requires additional approval before coverage activates. This is a coverage structure decision, not a clinical judgment that the drug is inappropriate for you.

## Why This Denial Is Appealable

Every ACA-compliant plan and ERISA plan must offer a meaningful exception and appeal process:

• Formulary exception / coverage exception: You may request that Aetna cover Ohtuvayre at an in-formulary cost-sharing level if a formulary alternative is medically inappropriate for you. This is separate from (and often faster than) a standard appeal.
• Internal appeal (ACA §2719 / ERISA §503): If the exception is denied, you may file a formal internal appeal. Plans must decide within standard timelines set by regulation.
• External review (ACA §2719): After internal exhaustion — or at the 4-month mark — an Independent Review Organization can override the plan. The window for requesting external review is typically 4 months from the denial notice.
• Expedited track: Available when a standard timeline would seriously jeopardize your health.

## Documentation to Gather

1. Formulary alternative failure history: A dated list of each formulary-covered COPD inhaler you have tried (bronchodilators, ICS combinations, roflumilast if applicable), with your physician's note on why each was inadequate or caused unacceptable adverse effects. 2. Clinical contraindication or intolerance documentation: Chart notes or pharmacy records supporting why formulary alternatives cannot be used. 3. Prescriber medical-necessity letter: Your prescribing physician should state specifically that no covered alternative is clinically equivalent for your case and that Ohtuvayre is medically necessary. 4. FDA label reference: The prescriber's letter should reference the approved indication in the FDA prescribing information to establish the on-label basis for use.

## Criteria-Mapping Structure

Download Aetna's formulary exception criteria from aetna.com. List each requirement. Answer each with a specific chart fact — physician name, date, clinical finding. The goal is to leave no criterion unanswered. Attach all supporting records as tabbed exhibits.

## Next Step

Ask Aetna's pharmacy team whether Ohtuvayre is under active formulary review for future addition. Some plans will grant a temporary formulary exception while a drug is being evaluated. Document this conversation (date, representative name, reference number) and reference it in your formal appeal.